These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20811028)

  • 1. Issues related to risk evaluation and mitigation strategies in health-system pharmacy.
    Coffey J
    Am J Health Syst Pharm; 2010 Sep; 67(18):1512. PubMed ID: 20811028
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk evaluation and mitigation strategies: challenges and opportunities for health-system pharmacists.
    Stubbings J; Joshi RA; Hoffman JM
    Am J Health Syst Pharm; 2010 Sep; 67(18):1547-54. PubMed ID: 20811034
    [No Abstract]   [Full Text] [Related]  

  • 3. Where are risk evaluation and mitigation strategies headed?
    Johnson PE
    Am J Health Syst Pharm; 2010 Sep; 67(18):1511. PubMed ID: 20811027
    [No Abstract]   [Full Text] [Related]  

  • 4. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
    Kirschenbaum BE
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared REMS programs expanded in 2012.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(4):298, 303. PubMed ID: 23370134
    [No Abstract]   [Full Text] [Related]  

  • 8. Stakeholders urge overhaul of REMS programs: Standardization, better access, less paperwork sought.
    Traynor K
    Am J Health Syst Pharm; 2010 Sep; 67(17):1397-8. PubMed ID: 20720233
    [No Abstract]   [Full Text] [Related]  

  • 9. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary challenges and novel strategies for health-system formulary management.
    Heindel GA; McIntyre CM
    Am J Health Syst Pharm; 2018 Apr; 75(8):556-560. PubMed ID: 29626005
    [No Abstract]   [Full Text] [Related]  

  • 11. Pediatric Pharmacy Advocacy Group International Pediatric Pharmacy and Pharmacology Symposium, 24-26 April 2009; Orlando, Florida, USA.
    Wilde MI
    Paediatr Drugs; 2009; 11(5):333-48. PubMed ID: 19725599
    [No Abstract]   [Full Text] [Related]  

  • 12. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
    American Pharmacists Association ; Bough M
    J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 14. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications: introduction.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S2-3. PubMed ID: 19966076
    [No Abstract]   [Full Text] [Related]  

  • 15. What can be done to improve confidence and trust in the safety of the system for pharmaceutical products?
    Edwards BD; Whalen MD; Powell SM
    Curr Drug Saf; 2013 Feb; 8(1):1-3. PubMed ID: 23713998
    [No Abstract]   [Full Text] [Related]  

  • 16. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's sentinel network: a monumental task.
    Young D
    Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
    [No Abstract]   [Full Text] [Related]  

  • 18. Decision making in pharmacy practice: a case study.
    Sawyer WT
    Pharm Pract Manag Q; 1995 Jul; 15(2):82-8. PubMed ID: 10143602
    [No Abstract]   [Full Text] [Related]  

  • 19. Food and Drug Administration's Safe Use Initiative collaborating to reduce preventable harm from medications.
    U S Food And Drug Administration
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):76-93. PubMed ID: 20345207
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.
    Childs L; Alexander E; Duong MT
    Am J Health Syst Pharm; 2012 May; 69(10):885-9. PubMed ID: 22555085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.